La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

InspireMD Gestion

Gestion contrôle des critères 1/4

Le PDG InspireMD's est Marvin Slosman, nommé en Jan2020, a un mandat de 4.58 ans. La rémunération annuelle totale est $ 3.22M, composée du salaire de 14.6% et des bonus 85.4%, y compris les actions et options de la société. détient directement 0.025% des actions de la société, d'une valeur de $ 18.03K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 0.9 ans et 7.9 ans.

Informations clés

Marvin Slosman

Directeur général

US$3.2m

Rémunération totale

Pourcentage du salaire du PDG	14.6%
Durée du mandat du directeur général	4.7yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	less than a year
Durée moyenne du mandat des membres du conseil d'administration	8yrs

Mises à jour récentes de la gestion

Recent updates

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Jan 11

Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares

Feb 11

Analyse de la rémunération des PDG

Comment la rémunération de Marvin Slosman a-t-elle évolué par rapport aux bénéfices de InspireMD?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$3m	US$470k	-US$20m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$697k	US$433k	-US$18m
Sep 30 2022	n/a	n/a	-US$18m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$2m	US$410k	-US$15m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$1m	US$367k	-US$11m

Rémunération vs marché: La rémunération totale de Marvin ($USD 3.22M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de Marvin a augmenté alors que l'entreprise n'est pas rentable.

PDG

Marvin Slosman (60 yo)

4.7yrs

Titularisation

US$3,219,321

Compensation

Mr. Marvin L. Slosman has been President, Chief Executive Officer and Director of InspireMD, Inc. since January 1, 2020. Mr. Slosman served as Chief Operating Officer for MEDCURA Incorporated from May 2019...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Marvin Slosman	President	4.7yrs	US$3.22m	0.025% $ 17.6k
Craig Shore	CFO, Chief Administrative Officer	less than a year	US$1.80m	9.33% $ 6.6m
Shane Gleason	Chief Commercial Officer	1.1yrs	US$1.15m	2.11% $ 1.5m
Andrea Tommasoli	Chief Operating Officer	1.5yrs	US$359.27k	1.97% $ 1.4m
Amir Kohen	Senior Vice President of Finance & HR	less than a year	pas de données	pas de données
Patrick Verta	Executive Vice President of Clinical & Medical Affairs	less than a year	pas de données	0.72% $ 512.5k
Pete Ligotti	Executive VP & GM of North America	less than a year	pas de données	pas de données
Sol Barer	Special Advisor to the Board	no data	US$13.92k	pas de données

1.0yrs

Durée moyenne de l'emploi

61.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de NSPR n'est pas considérée comme expérimentée (ancienneté moyenne 0.9 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Marvin Slosman	President	4.7yrs	US$3.22m	0.025% $ 17.6k
Michael Berman	Independent Director	11.6yrs	US$380.25k	1.62% $ 1.1m
Elazer Edelman	Member of Advisory Board	no data	pas de données	pas de données
Thomas Kester	Independent Director	8yrs	US$385.25k	1.27% $ 898.3k
Antonio Colombo	Member of Advisory Board	no data	pas de données	pas de données
Alexandre Abizaid	Member of Advisory Board	no data	pas de données	pas de données
Martin B. Leon	Member of Advisory Board	no data	pas de données	pas de données
Eberhart Grube	Member of Advisory Board	no data	pas de données	pas de données
Paul Stuka	Independent Chairman of the Board	13.1yrs	US$574.93k	1.21% $ 856.8k
Kenneth Rosenfield	Chair of Scientific Advisory Board	3.4yrs	pas de données	pas de données
Yaron Almagor	Member of Advisory Board	no data	pas de données	pas de données
Edo Kaluski	Member of Advisory Board	no data	pas de données	pas de données

8.0yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de NSPR sont considérés comme expérimentés (ancienneté moyenne 7.9 ans).

InspireMD Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Independent Director exercised options to buy US$153k worth of stock.

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Insider recently bought US$127k worth of stock

InspireMD, Inc. Announces Management Appointments

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

Recent updates

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023)

New minor risk - Share price stability

InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Independent Director exercised options to buy US$153k worth of stock.

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)

InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Insider recently bought US$127k worth of stock

Consensus EPS estimates fall by 13%

Price target increased by 18% to US$4.85

Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical Trial

InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023

InspireMD, Inc. Announces Management Appointments

Consensus EPS estimates upgraded to US$0.77 loss

Price target increased by 12% to US$4.35

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023

InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial

Consensus estimates of losses per share improve by 46%

InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investors

InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus revenue estimates decrease by 37%, EPS upgraded

Price target decreased to US$5.60

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insider recently bought US$68k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q2, 2022 Results on Aug 09, 2022

InspireMD, Inc. Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

InspireMD, Inc., Annual General Meeting, Aug 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$9.00

Full year 2021 earnings: EPS misses analyst expectations

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

InspireMD, Inc. to Report Q4, 2021 Results on Mar 08, 2022

InspireMD Appoints Adnan Siddiqui as Member of Its Scientific Advisory Board and Strategic Advisor

We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth Carefully

Insider recently bought US$50k worth of stock

Insider recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020)

We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate

InspireMD: Revolutionizing The Field Of Vascular Stenting

Insider recently bought US$93k worth of stock

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020)

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019)

Earnings beat expectations, revenue disappoints

InspireMD, Inc. to Report Q4, 2020 Results on Mar 09, 2021

InspireMD, Inc. Engages Hart Clinical Consultants to Conduct Clinical Trial for Cguard Carotid Stent System in the United States

Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares

InspireMD, Inc. Appoints Chris Metzger as Principal Investigator for CGuard Registration Trial in the United States

New 90-day high: US$0.82

InspireMD, Inc. has completed a Composite Units Offering in the amount of $18 million.

InspireMD, Inc. Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

New 90-day high: US$0.71

New 90-day high: US$0.44

Analysts update estimates

Third quarter 2020 earnings released: US$0.064 loss per share

Revenue beats expectations, earnings disappoint

Inspiremd, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing

InspireMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020